Cited by 159Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

Molinari, Francesca, Felicioni, Lara, Buscarino, Michela, De Dosso, Sara, Buttitta, Fiamma, Malatesta, Sara, Movilia, Alessandra, Luoni, Marco, Boldorini, Renzo, Alabiso, Oscar, Girlando, Salvatore, Soini, Barbara, Spitale, Alessandra, Di Nicolantonio, Federica, Saletti, Piercarlo, Crippa, Stefano, Mazzucchelli, Luca, Marchetti, Antonio, Bardelli, Alberto, Frattini, Milo·2011·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-10-3137

Open this paper in CoChat — free account

Abstract

Purpose: KRAS mutations represent the main cause of resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) in metastatic colorectal cancer (mCRC). We evaluated whether highly sensitive methods for KRAS investigation improve the accuracy of predictions of anti-EGFR MoAbs efficacy. Experimental Design: We retrospectively evaluated objective tumor responses in mCRC patients treated with cetuximab or panitumumab. KRAS codons 12 and 13 were examined by direct sequencing, MALDI-TOF MS, mutant-enriched PCR, and engineered mutant-enriched PCR, which have a sensitivity of 20%, 10%, 0.1%, and 0.1%, respectively. In addition, we analyzed KRAS codon 61, BRAF, and PIK3CA by direct sequencing and PTEN expression by immunohistochemistry. Results: In total, 111 patients were considered. Direct sequencing revealed mutations in codons 12 and 13 of KRAS in 43/111 patients (39%) and BRAF mutations in 9/111 (8%), with almost all of these occurring in nonresponder patients. Using highly sensitive methods, we identified up to 13 additional KRAS mutations compared with direct sequencing, all occurring in nonresponders. By analyzing PIK3CA and PTEN, we found that of these 13 patients, 7 did not show any additional alteration in the PI3K pathway. Conclusions: The application of highly sensitive methods for the detection of KRAS mutations significantly improves the identification of mCRC patients resistant to anti-EGFR MoAbs. Clin Cancer Res; 17(14); 4901–14. ©2011 AACR.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-3137

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citation
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Douillard, J., Siena, S., Cassidy, J., Tabernero, J. M., Burkes, R. L., Barugel, M. E., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,829
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Bokemeyer, C., Bondarenko, I., Makhson, A. M., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,646
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 5×
“Furthermore, mutational analyses were performed using widely accepted protocols (4, 17), and the laboratory”
BackgroundMethodResultInfluentialSelf-citation

Show all 51 references

Sorted by citations

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Self-citation
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513
Self-citation
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 460
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
Therkildsen, C., Bergmann, T. K., Schnack, T. H., Ladelund, S., & Nilbert, M. C. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.895036 · Cited by 406
The Implications of Clonal Genome Evolution for Cancer Medicine
Aparicio, S. A. J. R., & Caldas, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204892 · Cited by 361
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines
Schlicker, A., Beran, G. J., Chresta, C. M., McWalter, G., Pritchard, A., Weston, S. L., Runswick, S. K., Davenport, S., Heathcote, K., Alférez, D., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-66 · Cited by 267
Cancer biomarkers: selecting the right drug for the right patient
Kelloff, G. J., & Sigman, C. C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3651 · Cited by 256
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
Morelli, M. P., Overman, M. J., Dasari, A. N., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D. S., Eng, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv005 · Cited by 256
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
KRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed · doi:10.3748/wjg.v18.i37.5171 · Cited by 238
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 234
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine
Hiley, C. T., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome biology · doi:10.1186/s13059-014-0453-8 · Cited by 233
Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules
Grabocka, E., & Bar‐Sagi, D. (2016) · Cell · doi:10.1016/j.cell.2016.11.035 · Cited by 208
Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens
Hadd, A. G., Houghton, J., Choudhary, A. K., Sah, S., Chen, L., Marko, A. C., Sanford, T., Buddavarapu, K., Krosting, J., Garmire, L. X., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.11.006 · Cited by 184
The current understanding on the impact of KRAS on colorectal cancer
Meng, M., Zhong, K., Jiang, T., Liu, Z., Kwan, H. Y., & Su, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111717 · Cited by 171
Clinical Relevance of KRAS -Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
Laurent‐Puig, P., Pekin, D., Normand, C., Kotsopoulos, S. K., Nizard, P., Perez‐Toralla, K., Rowell, R. K., Olson, J., Srinivasan, P., Corre, D. L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0983 · Cited by 166
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
Imamura, Y., Lochhead, P. J., Yamauchi, M., Kuchiba, A., Qian, Z. R., Liao, X., Nishihara, R., Jung, S., Wu, K., Nosho, K., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-135 · Cited by 153
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
Normanno, N., Rachiglio, A. M., Lambiase, M., Martinelli, E., Fenizia, F., Esposito, C., Roma, C., Troiani, T., Rizzi, D., Tatangelo, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv176 · Cited by 150
Therapeutic target database update 2014: a resource for targeted therapeutics
Chu, Q., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y., Yang, S. Y., Wei, Y., Tao, L., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1129 · Cited by 122
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study
Cremolini, C., Morano, F., Moretto, R., Berenato, R., Tamborini, E., Perrone, F., Rossini, D., Gloghini, A., Busico, A., Zucchelli, G., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx546 · Cited by 126
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu230 · Cited by 116
Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
Tougeron, D., Lecomte, T., Pagès, J., Villalva, C., Collin, C., Ferru, A., Tourani, J. M., Silvain, C., Levillain, P., & Karayan, L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds620 · Cited by 115
Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection
Dong, L., Wang, S., Fu, B., & Wang, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27368-3 · Cited by 102
Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies
Sah, S., Chen, L., Houghton, J. F., Kemppainen, J., Marko, A. C., Zeigler, R., & Latham, G. J. (2013) · Genome Medicine · doi:10.1186/gm481 · Cited by 99
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 106
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
Fornaro, L., Lonardi, S., Masi, G., Loupakis, F., Bergamo, F., Salvatore, L., Cremolini, C., Schirripa, M., Vivaldi, C., Aprile, G., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt165 · Cited by 99
Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 100
Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma
Weirauch, U., Beckmann, N., Thomas, M., Grünweller, A., Huber, K., Bracher, F., Hartmann, R. K., & Aigner, A. M. (2013) · Neoplasia · doi:10.1593/neo.13172 · Cited by 96
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., Beghelli, S., Greenhalf, W., Costello, E., Schanne, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060870 · Cited by 93
Translational research in oncology—10 years of progress and future prospects
Doroshow, J. H., & Kummar, S. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.158 · Cited by 91
Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree?
Blank, A., ROBERTS, D. E., Dawson, H., Zlobec, I., & Lugli, A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00234 · Cited by 93
KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis
Westwood, M. E., van Asselt, A. D. I., Ramaekers, B. L. T., Whiting, P. F., Joore, M. A., Armstrong, N., Noake, C., Ross, J., Severens, J. L., & Kleijnen, J. (2014) · Health Technology Assessment · doi:10.3310/hta18620 · Cited by 85
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
de Castro, D. G., Angulo, B., Gomez, B., Mair, D., Martinez, R., Suárez‐Gauthier, A., Shieh, F., Velez, M., Brophy, V. H., Lawrence, H. J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.259 · Cited by 79
Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases
Andreou, A., Kopetz, S., Maru, D. M., Chen, S. S., Zimmitti, G., Brouquet, A., Shindoh, J., Curley, S. A., Garrett, C. R., Overman, M. J., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826b4dcc · Cited by 79
Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy
Wu, D., Wang, D. C., Cheng, Y., Qian, M., Zhang, M., Shen, Q., & Wang, X. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.006 · Cited by 77
Tumor Heterogeneity Revealed byKRAS,BRAF, andPIK3CAPyrosequencing:KRASandPIK3CAIntratumor Mutation Profile Differences and Their Therapeutic Implications
Kosmidou, V., Oikonomou, E., Vlassi, M., Avlonitis, S., Katseli, A., Tsipras, I., Mourtzoukou, D., Kontogeorgos, G., Zografos, G., & Pintzas, A. (2013) · Human Mutation · doi:10.1002/humu.22496 · Cited by 74
Molecular Genotyping of Follicular Variant of Papillary Thyroid Carcinoma Correlates with Diagnostic Category of Fine-Needle Aspiration Cytology: Values of RAS Mutation Testing
Lee, S. R., Jung, C. K., Kim, T. E., Bae, J. S., Jung, S. L., Choi, Y. J., & Kang, C. S. (2013) · Thyroid · doi:10.1089/thy.2012.0640 · Cited by 71
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group
Wong, N. A. C. S., de Castro, D. G., Salto‐Tellez, M., Butler, R., Díaz‐Cano, S. J., Ilyas, M., Newman, W. G., Shaw, E. C., Tanière, P., & Walsh, S. V. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202467 · Cited by 70
Targeting BRAF and RAS in Colorectal Cancer
Bellio, H., Fumet, J.-D., & Ghiringhelli, F. (2021) · Cancers · doi:10.3390/cancers13092201 · Cited by 71
Implications of genetic heterogeneity in cancer
Schmitt, M. W., Prindle, M. J., & Loeb, L. A. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06590.x · Cited by 65
Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach
Blanco, M., Concha, Á., Figueroa, A., Garrido, F., & Valladares‐Ayerbes, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160613610 · Cited by 67
FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma
Pietrantonio, F., Maggi, C., Fanetti, G., Iacovelli, R., Bartolomeo, M. D., Ricchini, F., D, M. D. M., Perrone, F., Baratti, D., D, S. K. M., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0106 · Cited by 64
COLD-PCR Enrichment of Rare Cancer Mutations prior to Targeted Amplicon Resequencing
Milbury, C. A., Correll, M., Quackenbush, J. F., Rubio, R., & Makrigiorgos, G. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.176198 · Cited by 64
KRASandBRAFgene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients
Ye, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i5.1595 · Cited by 68
Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians
Phua, L. C., Chue, X. P., Koh, P. K., Cheah, P. Y., Chan, E. C. Y., & Ho, H. K. (2014) · Oncology Reports · doi:10.3892/or.2014.3193 · Cited by 62
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
Nigro, C. L., Ricci, V., Vivenza, D., Granetto, C., Fabozzi, T., Miraglio, E., & Merlano, M. C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6944 · Cited by 61
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
Sclafani, F., Chau, I., Cunningham, D., Hahne, J. C., Vlachogiannis, G., Eltahir, Z., Lampis, A., Braconi, C., Kalaitzaki, E., de Castro, D. G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19212-5 · Cited by 63
Expanded RAS: Refining the Patient Population
Atreya, C. E., Corcoran, R. B., & Kopetz, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9325 · Cited by 63
Nanofluidic Digital PCR for KRAS Mutation Detection and Quantification in Gastrointestinal Cancer
Azuara, D., Morell, M., Gausachs, M., Rodríguez‐Moranta, F., Fabregat, J., Busquets, J., Peláez, N., Boadas, J., Galter, S., Moreno, V. R., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.186577 · Cited by 60
K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.049 · Cited by 56
PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine
Davies, E. J., Durban, V. M., Méniel, V. S., Williams, G. T., & Clarke, A. R. (2013) · The Journal of Pathology · doi:10.1002/path.4312 · Cited by 54
Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma
Lee, S., Brophy, V. H., Cao, J., Velez, M., Hoeppner, C., Soviero, S., & Lawrence, H. J. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1180-0 · Cited by 52
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
Liu, X., George, G. C., Tsimberidou, A. M., Naing, A., Wheler, J. J., Kopetz, S., Fu, S., Piha-Paul, S. A., Eng, C., Falchook, G. S., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1701-3 · Cited by 52
High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer
Jeantet, M., Tougeron, D., Tachon, G., Cortes, U., Archambaut, C., Fromont, G., & Karayan, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122015 · Cited by 51
Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
Mezzapelle, R., Miglio, U., Rena, O., Paganotti, A., Allegrini, S., Antona, J., Molinari, F., Frattini, M., Monga, G., Alabiso, O., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.130 · Cited by 47
Self-citation
Analytic performance studies and clinical reproducibility of a real-time PCRassay for the detection of epidermal growth factor receptor gene mutations informalin-fixed paraffin-embedded tissue specimens of non-small cell lungcancer
O’Donnell, P., Ferguson, J., Shyu, J., Current, R., Rehage, T., Tsai, J., Christensen, M. L., Tran, H. B., Chien, S., Shieh, F., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-210 · Cited by 46
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis
Chen, J., Ye, Y., Sun, H., & Shi, G. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2005-9 · Cited by 48
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
Pietrantonio, F., Berenato, R., Maggi, C., Caporale, M., Milione, M., Perrone, F., Tamborini, E., Baratti, D., D, S. K. M., Mariani, L., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0877-x · Cited by 46
RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
Helden, E. J. V., Angus, L., van Oordt, C. W. M. D. H., Heideman, D. A. M., Boon, E., van Es, S. C., Radema, S. A., van Herpen, C. M. L., de Groot, D. J. A., de Vries, E. G. E., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12550 · Cited by 75
Single Cell Transcriptome in Colorectal Cancer—Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells
Tieng, F. Y. F., Baharudin, R., Abu, N., Yunos, R. I. M., Lee, L., & Mutalib, N. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00135 · Cited by 45
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations
Yao, Y.-M., Donoho, G. P., Iversen, P. W., Zhang, Y., Horn, R. D. V., Forest, A., Novosiadly, R. D., Webster, Y., Ebert, P. J., Bray, S. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3250 · Cited by 45
Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
Stefano, A. D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9732 · Cited by 45
A new approach for prediction of tumor sensitivity to targeted drugs based on functional data
Berlow, N., Davis, L. E., Cantor, E. L., Séguin, B., Keller, C., & Pal, R. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-239 · Cited by 43
RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer
Waring, P. M., Tie, J., Maru, D. M., & Karapetis, C. S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.10.006 · Cited by 41
Toxicogenomics and Cancer Susceptibility: Advances with Next-Generation Sequencing
Ning, B., Su, Z., Mei, N., Hong, H., Deng, H., Shi, L. M., Fuscoe, J. C., & Tolleson, W. H. (2014) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2014.907460 · Cited by 37
Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie
Loree, J. M., Kopetz, S., & Raghav, K. P. S. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.01 · Cited by 36
Detection of Low-Abundance KRAS Mutations in Colorectal Cancer Using Microfluidic Capillary Electrophoresis-Based Restriction Fragment Length Polymorphism Method with Optimized Assay Conditions
Zhang, H., Song, J., Ren, H., Xu, Z., Wang, X., Shan, L., & Jin, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054510 · Cited by 36
KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy
Trisolini, E., Armellini, E., Paganotti, A., Veggiani, C., Bozzola, C., Frattini, M., Pizio, C., Mancuso, G., Andorno, S., & Boldorini, R. L. (2017) · Pathology · doi:10.1016/j.pathol.2016.12.348 · Cited by 36
Self-citation
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab
Musella, V., Pietrantonio, F., Buduo, E. D., Iacovelli, R., Martinetti, A., Sottotetti, E., Bossi, I. E., Maggi, C., Bartolomeo, M. D., de Braud, F., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29493 · Cited by 35
Systematic review/Meta-analysis Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients
Huang, L., Liu, Z., Deng, D., Tan, A., Liao, M., Mo, Z., & Yang, X. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.40728 · Cited by 37
KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond
Malapelle, U., Carlomagno, C., Luca, C. D., Bellevicine, C., & Troncone, G. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201835 · Cited by 34
Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer
Tan, E. S., Fan, W., Knepper, T. C., Schell, M. J., Şahin, İ. H., Fleming, J. B., & Xie, H. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00898-7 · Cited by 32
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
Bartolomeo, M. D., Pietrantonio, F., Perrone, F., Dotti, K. F., Lampis, A., Bertan, C. M., Beretta, E., Rimassa, L., Carbone, C., Biondani, P., et al. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0283-8 · Cited by 31
KRAS mutation testing in colorectal cancer as an example of the pathologist’s role in personalized targeted therapy: a practical approach
Domagała, P., Hybiak, J., Sulżyc‐Bielicka, V., Cybulski, C., Ryś, J., & Domagała, W. (2012) · Polish Journal of Pathology · doi:10.5114/pjp.2012.31499 · Cited by 31
KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics
Rechsteiner, M., von Teichman, A., Rüschoff, J. H., Fankhauser, N., Pestalozzi, B. C., Schraml, P., Weber, A., Wild, P. J., Zimmermann, D. R., & Moch, H. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.02.001 · Cited by 30
KRAS mutations: Analytical considerations
Herreros‐Villanueva, M., Chen, C.-C., Yuan, S. F., Liu, T., & Er, T. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.049 · Cited by 31
Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma
Weirauch, U., Beckmann, N., Thomas, M., Grünweller, A., Huber, K., Bracher, F., Hartmann, R. K., & Aigner, A. M. (2013) · Neoplasia · doi:10.1593/neo.13150 · Cited by 30
RNA biomarkers in colorectal cancer
Bustin, S. A., & Murphy, J. (2012) · Methods · doi:10.1016/j.ymeth.2012.10.003 · Cited by 29
Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal Cancer
Dono, M., Massucco, C., Chiara, S., Sonaglio, C., Mora, M., Truini, A., Cerruti, G., Zoppoli, G. M., Ballestrero, A., Truini, M., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00175 · Cited by 28
High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
Brunsell, T. H., Sveen, A., Bjørnbeth, B. A., Røsok, B. I., Danielsen, S. A., Brudvik, K. W., Berg, K. C. G., Johannessen, B., Cengija, V., Abildgaard, A., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.09.003 · Cited by 29
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens
Pietrantonio, F., Perrone, F., Biondani, P., Maggi, C., Lampis, A., Bertan, C. M., Venturini, F., Tondulli, L., Ferrari, D., Ricci, V., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26343 · Cited by 28
Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers.
Al-Shamsi, H. O., Alhazzani, W. A., & Wolff, R. A. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2015.016 · Cited by 28
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases
Pietrantonio, F., Mazzaferro, V., Miceli, R., Cotsoglou, C., Melotti, F., Fanetti, G., Perrone, F., Biondani, P., Muscarà, C., Bartolomeo, M. D., et al. (2015) · Medical Oncology · doi:10.1007/s12032-015-0638-3 · Cited by 28
Augmented O‐Glc NA cylation of AMP ‐activated kinase promotes the proliferation of LoVo cells, a colon cancer cell line
Ishimura, E., Nakagawa, T., Moriwaki, K., Hirano, S., Matsumori, Y., & Asahi, M. (2017) · Cancer Science · doi:10.1111/cas.13412 · Cited by 27
Aberrant promoter methylation of beta‐1,4 galactosyltransferase 1 as potential cancer‐specific biomarker of colorectal tumors
Poeta, M. L., Massi, E., Parrella, P., Pellegrini, P., Robertis, M. D., Copetti, M., Rabitti, C., Perrone, G., Muda, A. O., Molinari, F., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21998 · Cited by 26
Self-citation
Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status
Pietrantonio, F., Maggi, C., Bartolomeo, M. D., Facciorusso, M. G., Perrone, F., Testi, M., Iacovelli, R., Miceli, R., Bossi, I. E., Leone, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092147 · Cited by 26
Differential strand separation at critical temperature: A minimally disruptive enrichment method for low-abundance unknown DNA mutations
Guha, M., Castellanos-Rizaldos, E., Liu, P., Mamon, H. J., & Makrigiorgos, G. M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1250 · Cited by 26
Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors
Geiersbach, K. B., Adey, N. B., Welker, N. C., Elsberry, D., Malmberg, E. M., Edwards, S., Downs-Kelly, E. P., Salama, M. E., & Bronner, M. P. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.12.004 · Cited by 27
KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer
Malapelle, U., Carlomagno, C., Salatiello, M., Stefano, A. D., Luca, C. D., Bianco, R., Marciano, R., Cimminiello, C., Bellevicine, C., Placido, S. D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.275 · Cited by 24
A novel Cu-MOFs nanosheet/BiVO4 nanorod-based ECL sensor for colorectal cancer diagnosis
Zhang, X., Wang, P., Liang, Z., Zhong, W., & Ma, Q. (2023) · Talanta · doi:10.1016/j.talanta.2023.124952 · Cited by 24
A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid
Myers, M. B., McKim, K. L., & Parsons, B. L. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21953 · Cited by 24
Rapid and accurate detection of KRAS mutations in colorectal cancers using the isothermal-based optical sensor for companion diagnostics
Jin, C. E., Yeom, S., Koo, B., Lee, T. Y., Lee, J. H., Shin, Y. M., & Lim, S. (2017) · Oncotarget · doi:10.18632/oncotarget.20038 · Cited by 23
Loopback rolling circle amplification for ultrasensitive detection of Kras gene
Xu, H. Y., Wu, D., Jiang, Y., Zhang, R., Wu, Q., Liu, Y., Li, F., & Wu, Z. (2016) · Talanta · doi:10.1016/j.talanta.2016.12.017 · Cited by 22
Optimization of routine KRAS mutation PCR ‐based testing procedure for rational individualized first‐line‐targeted therapy selection in metastatic colorectal cancer
Chrétien, A.-S., Harlé, A., Meyer-Lefebvre, M., Rouyer, M., Husson, M., Ramacci, C., Harter, V., Génin, P., Leroux, A., & Merlin, J. (2012) · Cancer Medicine · doi:10.1002/cam4.47 · Cited by 22
Personalized treatment for advanced colorectal cancer: KRAS and beyond
Karapetis, C. S., & Patel, G. S. (2013) · Cancer Management and Research · doi:10.2147/cmar.s35025 · Cited by 20
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study
Bartolomeo, M. D., Ciarlo, A., Bertolini, A., Barni, S., Verusio, C., Aitini, E., Pietrantonio, F., Iacovelli, R., Dotti, K. F., Maggi, C., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.020 · Cited by 21
Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer
Phua, L. C., Ng, H. W., Yeo, A. H. L., Chen, E., Lo, M., Cheah, P. Y., Chan, E. C. Y., Koh, P. K., & Ho, H. K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3560 · Cited by 21
KRAS Mutant Tumor Subpopulations can Subvert Durable Responses to Personalized Cancer Treatments
Parsons, B. L., & Myers, M. B. (2013) · Personalized Medicine · doi:10.2217/pme.13.1 · Cited by 21
Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status
Yong, Z. Z., Ching, G. T. H., & Ching, M. T. C. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2018.11.025 · Cited by 20

Authors: Molinari, F., Felicioni, L., Buscarino, M., De Dosso, S., Buttitta, F., Malatesta, S., Movilia, A., Luoni, M., Boldorini, R., Alabiso, O., Girlando, S., Soini, B., Spitale, A., Di Nicolantonio, F., Saletti, P., Crippa, S., Mazzucchelli, L., Marchetti, A., Bardelli, A., & Frattini, M.
Affiliations: Istituto Oncologico della Svizzera Italiana (CH)
Authors' Affiliations: 1Institute of Pathology; 2Ticino Cancer Registry, Locarno, Switzerland; 3Department of Pathology, Clinical Research Center, Center of Excellence on Aging, University-Foundation, Chieti, Italy; 4Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, Candiolo, Italy; 5Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Departments of 6Pathology and 7Oncology, Civil Hospital, Legnano, Italy; Departments of 8Medical Sciences and 9Oncology, University School of Medicine, Novara, Italy; Departments of 10Pathology and 11Medical Oncology, Santa Chiara Hospital, Trento, Italy; and 12FIRC Institute of Molecular Oncology, Milan, Italy
Istituto Cantonale di Patologia (CH)
ORCID: Malatesta, Sara
Boldorini, Renzo
Alabiso, Oscar
Crippa, Stefano
Marchetti, Antonio
Bardelli, Alberto
Frattini, Milo
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2011-07-15
Volume: 17
Issue: 14
Pages: 4901-4914
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-10-3137
OpenAlex: W2135672185
Cited by: 159
References: 51
Citations by year: 2025: 2 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 7 · 2018: 8 · 2017: 11 · 2016: 14 · 2015: 20 · 2014: 27 · 2013: 26 · 2012: 26
FWCI: 13.21
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: KRAS mutation, metastatic colorectal cancer, anti-EGFR monoclonal antibody, cetuximab, panitumumab, treatment resistance, BRAF mutation, PIK3CA, PTEN, PI3K signaling, MALDI-TOF mass spectrometry, direct sequencing, predictive biomarkers
MeSH terms: Aged, Antibodies, Monoclonal, Antineoplastic Agents, Base Sequence, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Prognosis, Proto-Oncogene Proteins, Sensitivity and Specificity, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Treatment Outcome, ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Kaplan-Meier Estimate, Class I Phosphatidylinositol 3-Kinases, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks